SlideShare a Scribd company logo
1 of 59
ROLE OF SBRT IN
LUNG CANCER
By
Dr. Ayush Garg
Senior Resident
Learning Objectives for JRs
 What is SBRT?
 Why need of SBRT?
 Difference between Conventional RT and SBRT
 Steps of SBRT
 Indications of SBRT
 Advantages & Disadvantages of SBRT
Learning Objectives for SRs
 Various dose regimes
 OAR dose tolerances
 Evidences of SBRT
Introduction
• SBRT is a noninvasive treatment
involving the precise delivery of
ablative dose radiation
• Compared with fractionated radiation,
SBRT achieves superior local control
and survival
• SBRT (also known as SABR) uses short courses of very high (ablative),
highly conformal, and dose-intensive RT precisely delivered to limited-size
targets.
• Current standard-of-care for early-stage, nonoperative NSCLC is
stereotactic body radiation therapy (SBRT)
Types of lesions
Peripheral lesions
• They are located > 2 cm from the primary bronchi or trachea
Central lesions
• Located within 2 cm of the proximal bronchial tree and/or
abutting mediastinal pleura
Ultra-Central lesions
• Lesions abutting the proximal bronchial tree
The black dashed line defines the location of tumors that are central relative to the proximal bronchial tree.
The term central has been widened to include the region within 2 cm in all directions of any mediastinal critical
structure, including the bronchial tree/trachea, esophagus, heart, brachial plexus, major vessels, spinal cord,
phrenic nerve, and recurrent laryngeal nerve. The region shaded red shows the trachea and main bronchi, and
lesions with a PTV which overlaps this region are considered as ultracentral.
b Example of an ultracentral tumor (planning target volume in red, and main bronchi/trachea in yellow).
c Example of a central tumor
Difference between SBRT & Normal
fractionation
Conventional Radiotherapy SBRT
The work flow
Pre-SBRT
work up
Simulation
(+/- 4DCT)
Tumor &
OAR
contouring
Plan
analysis &
acceptance
Trial setup &
off line
CBCT
Treatment
delivery &
review
Follow up &
data
collection
Pre requisites for SBRT
• Equipment
• Staff teaching and training
• Patient selection for SBRT
• Patient counselling
• Treatment planning
• Dose and fractionation
• Radiotherapy planning steps
• Inter- and intra-fraction image guidance
• Quality assurance
• Follow-up
Equipment
Mandatory
• C-arm linear accelerator with volumetric in-room image guidance
• Respiration correlated 4D-CT
Recommended
• Dedicated C-arm stereotactic linear accelerator (more advanced
IGRT, more precise accuracy)
• High-resolution MLC <10 mm
Staff teaching and training
• Written departmental protocols
• Multi-disciplinary project team for SBRT implementation and
application
• Structured follow-up for clinical outcome assessment
Patient selection for SBRT
SBRT is recommended in the NSCLC for patients with
 Stage I and II (T1–3,N0,M0)
 NSCLC who are medically inoperable
 High risk- elderly
 Refuse surgery after appropriate consultation
SBRT has no established role in small cell lung cancer
 PFT (FEV1 or DLCO
< 40%)
 DM/CAD
 Cerebral disease
 Pul. HTN
 PS 0-2
 Able to lie flat for at
least one hour
Early-Stage NSCLC (Stage I, selected node-negative Stage IIA)
• SBRT is recommended for patients who are medically inoperable or who
refuse to have surgery after thoracic surgery evaluation.
• SABR is also an appropriate option for patients with high surgical risk (able to
tolerate sublobar resection but not lobectomy [eg, age ≥75 years], poor lung
function).
• SABR has achieved good primary tumor control rates and overall survival,
and higher than conventionally fractionated radiotherapy, although not
proven equivalent to lobectomy
NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer
Patient Counseling
Comparison of SBRT with other local treatment options
Patient Positioning and Immobilization
• Stable and reproducible patient positioning is essential. If
possible, patients should be positioned with both arms above
the head as this position permits a greater choice of beam
positions.
• Reproducible setup can be achieved using a stable arm
support, in combination with knee support to improve patient
comfort.
Patient Positioning and Immobilization
Fusion Images
CT scan
• Planning CT scans should be acquired in treatment position,
and incorporate techniques for evaluating motion compensation
• A planning CT scan should include the entire lung volume, and
typically extends from the level of the cricoid cartilage to the
second lumbar vertebra
• Slice thickness of 2–3 mm is recommended
• IV contrast should be used
• 4D-CT is recommended
Fusion Images
PET scanning
The equipment used for patient immobilisation during PET scans
should be identical to that used for CT scanning and treatment
Target Volume Definitions
GTV
• CT with the settings: W= 1600 and L = 600 for parenchyma, and W=
400 and L = 20 for mediastinum should be used
• Elective nodal irradiation is not indicated in any patient
CTV
• In SBRT treatments, CTV margins are generally not used
ITV
• Target representing the range of GTV motion through the breathing
cycle
PTV
• ITV + 3 to 10 mm margin; Respiratory motion is a patient-specific
factor which should be determined before treatment, typically using a
pre-treatment 4D-CT or 4D PET/CT scan
Target Volume Definitions
Passive motion compensation strategies
• Abdominal compression
• Internal target volume (ITV) concept
• Mid-ventilation concept
• Jet-ventilation
Active motion compensation strategies
• Gating
• Breath hold
• Tracking
Application of one (either active or passive) 4D motion compensation
strategy is highly recommended
• Deep inspiration breath hold (DIBH) reduces tumour motion
while increasing the lung volume, resulting in decreased doses
to lung, and often also to the heart
Target volumes definition
PRV
For serial organs, including the spinal cord, the main bronchi, the
brachial plexus, the oesophagus and large blood vessels, the use
of a PRV might be helpful, since it reduces the probability of over
dosage
A 57-year-old man with medically inoperable NSCLC of the right upper lobe,
treated on an SBRT protocol: 30 Gy/1 fx.
(a) From the CT simulation, this image depicts the GTV during free breathing (red),
at maximum inhalation (green), and maximum exhalation (blue).
(b) ITV (lime) was generated by combining GTVs. PTV (light blue) = ITV + 5 mm.
(c) Isodose distribution using a 6-arc plan, 6 MV photons, prescribed to the 80%
isodose line
Stephans et al. l SBRT for Central Lung Tumors l 10/ 4/11 l 16
Beam Placement
Beam Placement
Dose and fractionation
Commonly Used Doses for SABR
Total Dose # Fractions Example Indications
25–34 Gy 1 Peripheral, small (<2 cm) tumors, esp.
>1 cm from chest wall
45–60 Gy 3 Peripheral tumors and >1 cm from chest
wall
48–50 Gy 4 Central or peripheral tumors <4–5 cm,
especially <1 cm from chest wall
50–55 Gy 5 Central or peripheral tumors, especially <1
cm from chest wall
60–70 Gy 8–10 Central tumors
NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer
PRINCIPLES OF RADIATION THERAPY
Treatment Planning
Mandatory
• 3D conformal treatment planning
• Type B algorithms
• Respiration correlated 4D-CT imaging
• ITV based motion management strategy
Recommended
• Dynamic IMRT planning (VMAT)
• Use of a fixed dose inhomogeneity in PTV
Treatment Planning
Dose calculations
Dose calculation algorithms currently used for lung radiotherapy
generally take into account changes in electron transport due to
density variations, and are referred to as so-called type B or
Monte Carlo based algorithms
Radiotherapy Planning
• Tumour and nodal changes
• Inter-fractional tumour shifts
• Intra-fractional tumour shifts
• Intra-fractional respiratory and cardiac motion
• Anatomical changes during fractionated radiotherapy
Inter- and intrafraction image guidance
Mandatory
• Daily pre-treatment volumetric image-guidance
• Recommended
• Daily pre-treatment 4D volumetric image-guidance (in-room 4D-
CT, 4D-CBCT)
Tumour and nodal changes
Inter-fractional tumour shifts
• Inter-fractional shifts between primary tumour and vertebra
positions range from 5 to 7 mm on average (3D vector), but
may be as high as 3 cm
• Image guidance and patient setup corrections are essential
Tumour and nodal changes
Intra-fractional tumour shifts
• The intra-fractional target shifts are usually of small magnitude,
ranging from 0.15 to 0.21 cm
• Intra-fractional drifts increase when treatment times exceed 34
min
Tumour and nodal changes
Intra-fractional respiratory and cardiac motion
• Increased motion has been observed in lower-lobe tumours, for
smaller primary tumours and for infra-carinal lymph nodes
• For tumours close to heart or aorta, cardiac-induced motion can
exceed respiratory motion due to large inter-patient variability,
patient-specific motion assessment should be performed
Dose distribution
Red Shell
• The Red Shell representing high-risk tissue is shown in red surrounding
the clinical target volume (CTV) shown in gray.
• The serial critical organs are shown in yellow on the right.
• The Red Shell is composed of two sub-shells, the Inner Red Shell (the
smaller red ring surrounding the CTV) and the Outer Red Shell (the bigger
red ring surrounding the Inner Red Shell).
• The internal boundary of the Inner Red
Shell is the CTV surface.
• The external boundary of the Inner Red
Shell is the planning target volume (PTV)
surface.
Red Shell
• The external boundary of the Outer Red Shell is where the biologically
effective dose (BED) drops to the constraint dose.
• The Red Shell is curved inward on the right side.
• This is the result of careful planning to spare a critical serial organ (yellow)
in near proximity.
• As a result, the dose may need to protrude outward on the opposite side,
generating a bigger Red Shell in that direction, at the ‘‘cost’’ of sparing the
critical organ.
NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer
Maximum Dose Constraints for SABR
OAR/Regimen 1 Fraction 3 Fractions 4 Fractions 5 Fractions
Spinal cord 14 Gy 18 Gy (6 Gy/fx) 26 Gy (6.5 Gy/fx) 30 Gy (6 Gy/fx)
Esophagus 15.4 Gy 27 Gy (9 Gy/fx) 30 Gy (7.5 Gy/fx) 105% of PTV
prescription
Brachial plexus 17.5 Gy 24 Gy (8 Gy/fx) 27.2 Gy (6.8 Gy/fx) 32 Gy (6.4 Gy/fx)
Heart/ pericardium 22 Gy 30 Gy (10 Gy/fx) 34 Gy (8.5 Gy/fx) 105% of PTV
prescription
Great vessels 37 Gy NS 49 Gy (12.25 Gy/fx) 105% of PTV
prescription
Trachea &
proximal bronchi
20.2 Gy 30 Gy (10 Gy/fx) 34.8 Gy (8.7 Gy/fx) 105% of PTV
prescription
Rib 30 Gy 30 Gy (10 Gy/fx) 40 Gy (10 Gy/fx) NS
Skin 26 Gy 24 Gy (8 Gy/fx) 36 Gy (9 Gy/fx) 32 Gy (6.4 Gy/fx)
Stomach 12.4 Gy NS 27.2 Gy (6.8 Gy/fx) NS
*Based on constraints used in recent RTOG SABR trials (RTOG 0618, 0813, & 0915) ^for central tumor location. NS = not specified
Toxicity
Follow up
Mandatory
• Follow-up according to published guidelines
• FDG-PET imaging in case of suspected local recurrence
Recommended
• Routine biopsy confirmation of imaging-defined local failure only
in patients who are likely to undergo salvage therapy
Quality Assurance
Mandatory
• Intensified quality assurance (mechanical accuracy of 1.25 mm and a
dosimetric accuracy of 3% in a lung phantom inside the treatment field)
• Small field dosimetry detectors for commissioning
• Quality assurance of in-room image-guidance systems and of the 4D-
CT scanner
• Weekly checks of the mechanical accuracy of the delivery system
• Daily quality checks of the alignment of the IGRT system with the MV
treatment beam
Evidences
A 7-year follow-up showed that overall survival rates were 55.7% at 5 years and
47.5% at 7 years.
In 12 patients (18.5%), a second primary lung carcinoma developed after SABR
at a median of 35 months (range, 5–67 months); 27% (18/65) had disease
recurrence a median of 14.5 months (range, 4.3–71.5 months) after SABR.
• In conventionally fractionated
RT,
• 3-year survival is only about
20% to 35%
• Local failure rates of about
40% to 60%
• In SBRT
• Generally more than 85%, and
about 60% at 3 years (median
survival, 4 years), respectively
In Medically inoperable patients
Indiana (Timmerman JCO 2006; Fakiris, IJROBP 2009)
• n=70
• T1–3N0 (≤7 cm)
• 60–66 Gy in 3 fx over 1–2 weeks.
• Three-year LC 88%, CSS 82%, OS 43%, regional failure 9%, and
distant failure 13%.
• Patients with central tumors had increased risk of grade 3–5 toxicity
(27% vs 10%).
• Established “no-fly-zone” of 2 cm surrounding proximal
bronchial tree for 3-fraction treatment.
Onishi (Cancer, 2004)
• n=245
• T1–2N0 treated
• 18–75 Gy in 1–22 fx
• LF was 8% for BED ≥100 Gy vs 26% for BED <100 Gy.
• Three-year OS was 88% for BED ≥100 Gy vs 69% for BED
<100 Gy.
RTOG 0236 (Timmerman 2010)
• T1–3N0 (≤5 cm), medically inoperable tumors >2 cm from
proximal bronchial tree treated
• SBRT 20 Gy × 3 over 1.5–2 weeks (54 Gy applying
heterogeneity correction).
• GTV = CTV. PTV = 0.5 cm axial margin and 1 cm
superior/inferior margin.
• 5-year LC 93%, LRC 62%, 31% DM, DFS 26%, OS 40%.
RTOG 0915 (Videtic IJROBP 2015)
• Phase II randomized study of 34 Gy in 1 fraction vs 48 Gy in 4
fractions
• Medically inoperable T1-3N0 (≤5 cm) NSCLC
• Single fraction arm had lower risk of serious adverse events
(10.3 vs 13.3%).
• 2-year primary control, OS, and DFS were 97% vs 93%, 61% vs
77%, and 56% vs 71%, respectively.
RTOG 0618 (Timmerman ASCO 2013)
• Medically operable T1-T3N0 (≤5 cm) NSCLC >2 cm from
proximal bronchial tree
• 60 Gy in 3 fractions (54 Gy with heterogeneity correction).
• 2-year primary failure rate 7.8%, local failure (including
ipsilateral lobe) 19.2%, OS 84%. 16% grade 3 toxicity
RTOG 0813 (Bezjak ASTRO 2016)
• Phase I/II dose escalation trial for medically inoperable early-
stage NSCLC with centrally located lesions (<2 cm from the
bronchial tree)
• Arm I- 57.5 Gy (n=38), Arm II-60 Gy (n=33).
• Dose escalated from 50 Gy in 5 fractions to 60 Gy in 5 fractions.
• 2 yr LC 88–89%, PFS 52–55%, OS 70–73%, grade 3 toxicity 6–
7%
VUMC (Senthi, Lancet Oncol 2012)
• n=676
• PET+ clinical stage T1–2 N0 NSCLC
• 2/5-yr LF 5/11%, regional failure 8/13%, DM 15/20%.
SBRT VS SURGERY
Two randomized trials of surgery vs SBRT for operable early-
stage NSCLC failed to accrue (STARS and ROSEL)
Combined ROSEL/STARS analysis (Chang Lancet Oncol
2015):
• n=58 patients from two trials
• T1-T2 (<4 cm) N0 medically operable NSCLC
• SBRT (54 Gy in 3 fractions, 50 Gy in 4 fractions if central) vs
lobectomy and mediastinal lymph node dissection.
• 3-year OS improved for SBRT (95%) vs surgery (79%). Grade
3–4 toxicity 10% for SBRT vs 44% for surgery.
SBRT VS SURGERY
• JoLT-Ca STABLE-MATES trial (NCT02468024)
• VALOR (Veterans Affairs Lung cancer surgery Or stereotactic
Radiotherapy trial, NCT02984761)
• SABRTOOTH (NCT02629458)
Trials under going
SBRT VS SURGERY
Conclusion
It is a form of high precision radiotherapy delivery technique
• Needs to account for tumor motion
• Needs to be accurate
• Needs to have reproducible setup prior to treatment
Indications
• Stage I–II, inoperable, T1-3N0M0   Definitive SBRT not 3D
• Medically inoperable
• Operable disease who are high risk, elderly
• Refuse surgery
SABR for Node-Negative Early-Stage NSCLC
• BED ≥100 Gy are associated with significantly better local control and survival
• For central and ultra-central tumors 4 to 10 fraction regimens are effective and
safe
• SABR is most commonly used for tumors up to 5 cm in size
SBRT has a Developing role
• Boost following definitive chemoradiation in management of LA-NSCLC
• Re-irradiation of locally recurrent disease
• Intrathoracic oligometastases from various primary histologies
Role of SBRT in lung cancer
Role of SBRT in lung cancer

More Related Content

What's hot

Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy
fondas vakalis
 

What's hot (20)

RE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCERRE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCER
 
Accelerated partial breast irradiation
Accelerated partial breast irradiationAccelerated partial breast irradiation
Accelerated partial breast irradiation
 
Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]Rrecent advances in linear accelerators [MR linac]
Rrecent advances in linear accelerators [MR linac]
 
Lung sbrt ppt
Lung  sbrt pptLung  sbrt ppt
Lung sbrt ppt
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniques
 
Motion Management in Radiation Therapy
Motion Management in Radiation TherapyMotion Management in Radiation Therapy
Motion Management in Radiation Therapy
 
RT breast apbi
RT breast apbiRT breast apbi
RT breast apbi
 
Esophagus Contouring.pptx
Esophagus Contouring.pptxEsophagus Contouring.pptx
Esophagus Contouring.pptx
 
Prophylactic cranial irradiation
Prophylactic cranial irradiationProphylactic cranial irradiation
Prophylactic cranial irradiation
 
ICRU 38 nayana
ICRU 38 nayanaICRU 38 nayana
ICRU 38 nayana
 
Hypofractionation in breast cancer
Hypofractionation in breast cancerHypofractionation in breast cancer
Hypofractionation in breast cancer
 
radiation therapy in ca breast
radiation therapy in ca breast   radiation therapy in ca breast
radiation therapy in ca breast
 
Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy
 
image guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cerviximage guided brachytherapy carcinoma cervix
image guided brachytherapy carcinoma cervix
 
Concept of bed in radiobiology
Concept of bed in radiobiologyConcept of bed in radiobiology
Concept of bed in radiobiology
 
PARTICLE BEAM RADIOTHERAPY
PARTICLE BEAM RADIOTHERAPYPARTICLE BEAM RADIOTHERAPY
PARTICLE BEAM RADIOTHERAPY
 
4dct (2012)
4dct (2012)4dct (2012)
4dct (2012)
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiation
 
2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMOR2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMOR
 
craniospinal irradiation
craniospinal irradiationcraniospinal irradiation
craniospinal irradiation
 

Similar to Role of SBRT in lung cancer

Similar to Role of SBRT in lung cancer (20)

Radiotherapy planning in carcinoma cervix dr rekha
Radiotherapy planning in carcinoma cervix dr rekhaRadiotherapy planning in carcinoma cervix dr rekha
Radiotherapy planning in carcinoma cervix dr rekha
 
IMRT_Planning_MRM.pdf
IMRT_Planning_MRM.pdfIMRT_Planning_MRM.pdf
IMRT_Planning_MRM.pdf
 
Overview of ART in lung cancer
Overview of ART in lung cancerOverview of ART in lung cancer
Overview of ART in lung cancer
 
Imrt&amp;vmat
Imrt&amp;vmatImrt&amp;vmat
Imrt&amp;vmat
 
Radical Prostate Radiotherapy
Radical Prostate RadiotherapyRadical Prostate Radiotherapy
Radical Prostate Radiotherapy
 
RT in Ca esophagus
RT in Ca esophagusRT in Ca esophagus
RT in Ca esophagus
 
Lung plan evaluation
Lung plan evaluationLung plan evaluation
Lung plan evaluation
 
Radiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphomaRadiotherapy contouring guideline for non-hodgkin lymphoma
Radiotherapy contouring guideline for non-hodgkin lymphoma
 
Evaluation and imaging for lung SBRT
Evaluation and imaging for lung SBRTEvaluation and imaging for lung SBRT
Evaluation and imaging for lung SBRT
 
Icru 29,50 &62
Icru 29,50 &62Icru 29,50 &62
Icru 29,50 &62
 
Management of nasopharyngeal cancer
Management of nasopharyngeal cancerManagement of nasopharyngeal cancer
Management of nasopharyngeal cancer
 
Target volume definition
Target volume definitionTarget volume definition
Target volume definition
 
RADIOTHERAPY IN CARCINOMA BREAST (EARLY AND LOCALLY ADVANCED)
RADIOTHERAPY IN CARCINOMA BREAST (EARLY AND LOCALLY ADVANCED)RADIOTHERAPY IN CARCINOMA BREAST (EARLY AND LOCALLY ADVANCED)
RADIOTHERAPY IN CARCINOMA BREAST (EARLY AND LOCALLY ADVANCED)
 
Radiotherapy in Cervical Cancers1.ppt
Radiotherapy in Cervical Cancers1.pptRadiotherapy in Cervical Cancers1.ppt
Radiotherapy in Cervical Cancers1.ppt
 
SBRT: The Importance of Continuous Motion Management​
SBRT: The Importance of Continuous Motion Management​SBRT: The Importance of Continuous Motion Management​
SBRT: The Importance of Continuous Motion Management​
 
Cyberknife
Cyberknife Cyberknife
Cyberknife
 
ICRU 83
ICRU 83ICRU 83
ICRU 83
 
Summary of embrace protocol
Summary of embrace protocolSummary of embrace protocol
Summary of embrace protocol
 
Management of lung cancer
Management of lung cancerManagement of lung cancer
Management of lung cancer
 
Radiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumoursRadiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumours
 

More from DrAyush Garg

More from DrAyush Garg (20)

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
 
Overview of brain tumors
Overview of brain tumorsOverview of brain tumors
Overview of brain tumors
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
 
Carcinoma esophagus
Carcinoma esophagusCarcinoma esophagus
Carcinoma esophagus
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines final
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostate
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 

Recently uploaded

Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN DohaAbortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
Abortion pills in Kuwait Cytotec pills in Kuwait
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
د حاتم البيطار
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Levi Shapiro
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
mcsprintern12024
 
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
jvomprakash
 

Recently uploaded (20)

GENETICS and KIDNEY DISEASES /
GENETICS and KIDNEY DISEASES            /GENETICS and KIDNEY DISEASES            /
GENETICS and KIDNEY DISEASES /
 
Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN DohaAbortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
Abortion pills in Qatar (+919707208804) Get Cytotec Pills IN Doha
 
Lactation Mraining Management Session-2-Comm-Building-Conf.ppt
Lactation Mraining Management  Session-2-Comm-Building-Conf.pptLactation Mraining Management  Session-2-Comm-Building-Conf.ppt
Lactation Mraining Management Session-2-Comm-Building-Conf.ppt
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
 
Antiepileptic-Drugs-and-Congenital-Anomalies copy.pptx
Antiepileptic-Drugs-and-Congenital-Anomalies copy.pptxAntiepileptic-Drugs-and-Congenital-Anomalies copy.pptx
Antiepileptic-Drugs-and-Congenital-Anomalies copy.pptx
 
End of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response WorkshopEnd of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response Workshop
 
Leadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response WorkshopLeadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response Workshop
 
The 2024 Outlook for Older Adults: Healthcare Consumer Survey
The 2024 Outlook for Older Adults: Healthcare Consumer SurveyThe 2024 Outlook for Older Adults: Healthcare Consumer Survey
The 2024 Outlook for Older Adults: Healthcare Consumer Survey
 
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxSession-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
 
An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Navigating Conflict in PE Using Strengths-Based Approaches
Navigating Conflict in PE Using Strengths-Based ApproachesNavigating Conflict in PE Using Strengths-Based Approaches
Navigating Conflict in PE Using Strengths-Based Approaches
 
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
Unlock the Secrets to Optimizing Ambulatory Operations Efficiency and Change ...
 
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...ITM  HOSPITAL The hospital has also been recognised as the best emerging hosp...
ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...
 
Session-10-Infants-with-Special-meeds.ppt
Session-10-Infants-with-Special-meeds.pptSession-10-Infants-with-Special-meeds.ppt
Session-10-Infants-with-Special-meeds.ppt
 
Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.
 
Famous Indian Vedic Astrologer | Best Astrological Solutions UK
Famous Indian Vedic Astrologer | Best Astrological Solutions UKFamous Indian Vedic Astrologer | Best Astrological Solutions UK
Famous Indian Vedic Astrologer | Best Astrological Solutions UK
 
I urgently need a love spell caster to bring back my ex. +27834335081 How can...
I urgently need a love spell caster to bring back my ex. +27834335081 How can...I urgently need a love spell caster to bring back my ex. +27834335081 How can...
I urgently need a love spell caster to bring back my ex. +27834335081 How can...
 

Role of SBRT in lung cancer

  • 1. ROLE OF SBRT IN LUNG CANCER By Dr. Ayush Garg Senior Resident
  • 2. Learning Objectives for JRs  What is SBRT?  Why need of SBRT?  Difference between Conventional RT and SBRT  Steps of SBRT  Indications of SBRT  Advantages & Disadvantages of SBRT Learning Objectives for SRs  Various dose regimes  OAR dose tolerances  Evidences of SBRT
  • 3. Introduction • SBRT is a noninvasive treatment involving the precise delivery of ablative dose radiation • Compared with fractionated radiation, SBRT achieves superior local control and survival • SBRT (also known as SABR) uses short courses of very high (ablative), highly conformal, and dose-intensive RT precisely delivered to limited-size targets. • Current standard-of-care for early-stage, nonoperative NSCLC is stereotactic body radiation therapy (SBRT)
  • 4. Types of lesions Peripheral lesions • They are located > 2 cm from the primary bronchi or trachea Central lesions • Located within 2 cm of the proximal bronchial tree and/or abutting mediastinal pleura Ultra-Central lesions • Lesions abutting the proximal bronchial tree
  • 5. The black dashed line defines the location of tumors that are central relative to the proximal bronchial tree. The term central has been widened to include the region within 2 cm in all directions of any mediastinal critical structure, including the bronchial tree/trachea, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve. The region shaded red shows the trachea and main bronchi, and lesions with a PTV which overlaps this region are considered as ultracentral. b Example of an ultracentral tumor (planning target volume in red, and main bronchi/trachea in yellow). c Example of a central tumor
  • 6. Difference between SBRT & Normal fractionation
  • 8. The work flow Pre-SBRT work up Simulation (+/- 4DCT) Tumor & OAR contouring Plan analysis & acceptance Trial setup & off line CBCT Treatment delivery & review Follow up & data collection
  • 9. Pre requisites for SBRT • Equipment • Staff teaching and training • Patient selection for SBRT • Patient counselling • Treatment planning • Dose and fractionation • Radiotherapy planning steps • Inter- and intra-fraction image guidance • Quality assurance • Follow-up
  • 10. Equipment Mandatory • C-arm linear accelerator with volumetric in-room image guidance • Respiration correlated 4D-CT Recommended • Dedicated C-arm stereotactic linear accelerator (more advanced IGRT, more precise accuracy) • High-resolution MLC <10 mm
  • 11. Staff teaching and training • Written departmental protocols • Multi-disciplinary project team for SBRT implementation and application • Structured follow-up for clinical outcome assessment
  • 12. Patient selection for SBRT SBRT is recommended in the NSCLC for patients with  Stage I and II (T1–3,N0,M0)  NSCLC who are medically inoperable  High risk- elderly  Refuse surgery after appropriate consultation SBRT has no established role in small cell lung cancer  PFT (FEV1 or DLCO < 40%)  DM/CAD  Cerebral disease  Pul. HTN  PS 0-2  Able to lie flat for at least one hour
  • 13.
  • 14. Early-Stage NSCLC (Stage I, selected node-negative Stage IIA) • SBRT is recommended for patients who are medically inoperable or who refuse to have surgery after thoracic surgery evaluation. • SABR is also an appropriate option for patients with high surgical risk (able to tolerate sublobar resection but not lobectomy [eg, age ≥75 years], poor lung function). • SABR has achieved good primary tumor control rates and overall survival, and higher than conventionally fractionated radiotherapy, although not proven equivalent to lobectomy NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer
  • 15. Patient Counseling Comparison of SBRT with other local treatment options
  • 16. Patient Positioning and Immobilization • Stable and reproducible patient positioning is essential. If possible, patients should be positioned with both arms above the head as this position permits a greater choice of beam positions. • Reproducible setup can be achieved using a stable arm support, in combination with knee support to improve patient comfort.
  • 17. Patient Positioning and Immobilization
  • 18.
  • 19. Fusion Images CT scan • Planning CT scans should be acquired in treatment position, and incorporate techniques for evaluating motion compensation • A planning CT scan should include the entire lung volume, and typically extends from the level of the cricoid cartilage to the second lumbar vertebra • Slice thickness of 2–3 mm is recommended • IV contrast should be used • 4D-CT is recommended
  • 20. Fusion Images PET scanning The equipment used for patient immobilisation during PET scans should be identical to that used for CT scanning and treatment
  • 21. Target Volume Definitions GTV • CT with the settings: W= 1600 and L = 600 for parenchyma, and W= 400 and L = 20 for mediastinum should be used • Elective nodal irradiation is not indicated in any patient CTV • In SBRT treatments, CTV margins are generally not used ITV • Target representing the range of GTV motion through the breathing cycle PTV • ITV + 3 to 10 mm margin; Respiratory motion is a patient-specific factor which should be determined before treatment, typically using a pre-treatment 4D-CT or 4D PET/CT scan
  • 22. Target Volume Definitions Passive motion compensation strategies • Abdominal compression • Internal target volume (ITV) concept • Mid-ventilation concept • Jet-ventilation Active motion compensation strategies • Gating • Breath hold • Tracking Application of one (either active or passive) 4D motion compensation strategy is highly recommended
  • 23. • Deep inspiration breath hold (DIBH) reduces tumour motion while increasing the lung volume, resulting in decreased doses to lung, and often also to the heart
  • 24. Target volumes definition PRV For serial organs, including the spinal cord, the main bronchi, the brachial plexus, the oesophagus and large blood vessels, the use of a PRV might be helpful, since it reduces the probability of over dosage
  • 25. A 57-year-old man with medically inoperable NSCLC of the right upper lobe, treated on an SBRT protocol: 30 Gy/1 fx. (a) From the CT simulation, this image depicts the GTV during free breathing (red), at maximum inhalation (green), and maximum exhalation (blue). (b) ITV (lime) was generated by combining GTVs. PTV (light blue) = ITV + 5 mm. (c) Isodose distribution using a 6-arc plan, 6 MV photons, prescribed to the 80% isodose line
  • 26. Stephans et al. l SBRT for Central Lung Tumors l 10/ 4/11 l 16 Beam Placement
  • 29. Commonly Used Doses for SABR Total Dose # Fractions Example Indications 25–34 Gy 1 Peripheral, small (<2 cm) tumors, esp. >1 cm from chest wall 45–60 Gy 3 Peripheral tumors and >1 cm from chest wall 48–50 Gy 4 Central or peripheral tumors <4–5 cm, especially <1 cm from chest wall 50–55 Gy 5 Central or peripheral tumors, especially <1 cm from chest wall 60–70 Gy 8–10 Central tumors NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer PRINCIPLES OF RADIATION THERAPY
  • 30. Treatment Planning Mandatory • 3D conformal treatment planning • Type B algorithms • Respiration correlated 4D-CT imaging • ITV based motion management strategy Recommended • Dynamic IMRT planning (VMAT) • Use of a fixed dose inhomogeneity in PTV
  • 31. Treatment Planning Dose calculations Dose calculation algorithms currently used for lung radiotherapy generally take into account changes in electron transport due to density variations, and are referred to as so-called type B or Monte Carlo based algorithms
  • 32. Radiotherapy Planning • Tumour and nodal changes • Inter-fractional tumour shifts • Intra-fractional tumour shifts • Intra-fractional respiratory and cardiac motion • Anatomical changes during fractionated radiotherapy
  • 33. Inter- and intrafraction image guidance Mandatory • Daily pre-treatment volumetric image-guidance • Recommended • Daily pre-treatment 4D volumetric image-guidance (in-room 4D- CT, 4D-CBCT)
  • 34. Tumour and nodal changes Inter-fractional tumour shifts • Inter-fractional shifts between primary tumour and vertebra positions range from 5 to 7 mm on average (3D vector), but may be as high as 3 cm • Image guidance and patient setup corrections are essential
  • 35. Tumour and nodal changes Intra-fractional tumour shifts • The intra-fractional target shifts are usually of small magnitude, ranging from 0.15 to 0.21 cm • Intra-fractional drifts increase when treatment times exceed 34 min
  • 36. Tumour and nodal changes Intra-fractional respiratory and cardiac motion • Increased motion has been observed in lower-lobe tumours, for smaller primary tumours and for infra-carinal lymph nodes • For tumours close to heart or aorta, cardiac-induced motion can exceed respiratory motion due to large inter-patient variability, patient-specific motion assessment should be performed
  • 38. Red Shell • The Red Shell representing high-risk tissue is shown in red surrounding the clinical target volume (CTV) shown in gray. • The serial critical organs are shown in yellow on the right. • The Red Shell is composed of two sub-shells, the Inner Red Shell (the smaller red ring surrounding the CTV) and the Outer Red Shell (the bigger red ring surrounding the Inner Red Shell). • The internal boundary of the Inner Red Shell is the CTV surface. • The external boundary of the Inner Red Shell is the planning target volume (PTV) surface.
  • 39. Red Shell • The external boundary of the Outer Red Shell is where the biologically effective dose (BED) drops to the constraint dose. • The Red Shell is curved inward on the right side. • This is the result of careful planning to spare a critical serial organ (yellow) in near proximity. • As a result, the dose may need to protrude outward on the opposite side, generating a bigger Red Shell in that direction, at the ‘‘cost’’ of sparing the critical organ.
  • 40. NCCN Guidelines Version 7.2019 Non-Small Cell Lung Cancer Maximum Dose Constraints for SABR OAR/Regimen 1 Fraction 3 Fractions 4 Fractions 5 Fractions Spinal cord 14 Gy 18 Gy (6 Gy/fx) 26 Gy (6.5 Gy/fx) 30 Gy (6 Gy/fx) Esophagus 15.4 Gy 27 Gy (9 Gy/fx) 30 Gy (7.5 Gy/fx) 105% of PTV prescription Brachial plexus 17.5 Gy 24 Gy (8 Gy/fx) 27.2 Gy (6.8 Gy/fx) 32 Gy (6.4 Gy/fx) Heart/ pericardium 22 Gy 30 Gy (10 Gy/fx) 34 Gy (8.5 Gy/fx) 105% of PTV prescription Great vessels 37 Gy NS 49 Gy (12.25 Gy/fx) 105% of PTV prescription Trachea & proximal bronchi 20.2 Gy 30 Gy (10 Gy/fx) 34.8 Gy (8.7 Gy/fx) 105% of PTV prescription Rib 30 Gy 30 Gy (10 Gy/fx) 40 Gy (10 Gy/fx) NS Skin 26 Gy 24 Gy (8 Gy/fx) 36 Gy (9 Gy/fx) 32 Gy (6.4 Gy/fx) Stomach 12.4 Gy NS 27.2 Gy (6.8 Gy/fx) NS *Based on constraints used in recent RTOG SABR trials (RTOG 0618, 0813, & 0915) ^for central tumor location. NS = not specified
  • 42. Follow up Mandatory • Follow-up according to published guidelines • FDG-PET imaging in case of suspected local recurrence Recommended • Routine biopsy confirmation of imaging-defined local failure only in patients who are likely to undergo salvage therapy
  • 43. Quality Assurance Mandatory • Intensified quality assurance (mechanical accuracy of 1.25 mm and a dosimetric accuracy of 3% in a lung phantom inside the treatment field) • Small field dosimetry detectors for commissioning • Quality assurance of in-room image-guidance systems and of the 4D- CT scanner • Weekly checks of the mechanical accuracy of the delivery system • Daily quality checks of the alignment of the IGRT system with the MV treatment beam
  • 45. A 7-year follow-up showed that overall survival rates were 55.7% at 5 years and 47.5% at 7 years. In 12 patients (18.5%), a second primary lung carcinoma developed after SABR at a median of 35 months (range, 5–67 months); 27% (18/65) had disease recurrence a median of 14.5 months (range, 4.3–71.5 months) after SABR. • In conventionally fractionated RT, • 3-year survival is only about 20% to 35% • Local failure rates of about 40% to 60% • In SBRT • Generally more than 85%, and about 60% at 3 years (median survival, 4 years), respectively In Medically inoperable patients
  • 46. Indiana (Timmerman JCO 2006; Fakiris, IJROBP 2009) • n=70 • T1–3N0 (≤7 cm) • 60–66 Gy in 3 fx over 1–2 weeks. • Three-year LC 88%, CSS 82%, OS 43%, regional failure 9%, and distant failure 13%. • Patients with central tumors had increased risk of grade 3–5 toxicity (27% vs 10%). • Established “no-fly-zone” of 2 cm surrounding proximal bronchial tree for 3-fraction treatment.
  • 47. Onishi (Cancer, 2004) • n=245 • T1–2N0 treated • 18–75 Gy in 1–22 fx • LF was 8% for BED ≥100 Gy vs 26% for BED <100 Gy. • Three-year OS was 88% for BED ≥100 Gy vs 69% for BED <100 Gy.
  • 48. RTOG 0236 (Timmerman 2010) • T1–3N0 (≤5 cm), medically inoperable tumors >2 cm from proximal bronchial tree treated • SBRT 20 Gy × 3 over 1.5–2 weeks (54 Gy applying heterogeneity correction). • GTV = CTV. PTV = 0.5 cm axial margin and 1 cm superior/inferior margin. • 5-year LC 93%, LRC 62%, 31% DM, DFS 26%, OS 40%.
  • 49. RTOG 0915 (Videtic IJROBP 2015) • Phase II randomized study of 34 Gy in 1 fraction vs 48 Gy in 4 fractions • Medically inoperable T1-3N0 (≤5 cm) NSCLC • Single fraction arm had lower risk of serious adverse events (10.3 vs 13.3%). • 2-year primary control, OS, and DFS were 97% vs 93%, 61% vs 77%, and 56% vs 71%, respectively.
  • 50. RTOG 0618 (Timmerman ASCO 2013) • Medically operable T1-T3N0 (≤5 cm) NSCLC >2 cm from proximal bronchial tree • 60 Gy in 3 fractions (54 Gy with heterogeneity correction). • 2-year primary failure rate 7.8%, local failure (including ipsilateral lobe) 19.2%, OS 84%. 16% grade 3 toxicity
  • 51. RTOG 0813 (Bezjak ASTRO 2016) • Phase I/II dose escalation trial for medically inoperable early- stage NSCLC with centrally located lesions (<2 cm from the bronchial tree) • Arm I- 57.5 Gy (n=38), Arm II-60 Gy (n=33). • Dose escalated from 50 Gy in 5 fractions to 60 Gy in 5 fractions. • 2 yr LC 88–89%, PFS 52–55%, OS 70–73%, grade 3 toxicity 6– 7%
  • 52. VUMC (Senthi, Lancet Oncol 2012) • n=676 • PET+ clinical stage T1–2 N0 NSCLC • 2/5-yr LF 5/11%, regional failure 8/13%, DM 15/20%.
  • 53. SBRT VS SURGERY Two randomized trials of surgery vs SBRT for operable early- stage NSCLC failed to accrue (STARS and ROSEL)
  • 54. Combined ROSEL/STARS analysis (Chang Lancet Oncol 2015): • n=58 patients from two trials • T1-T2 (<4 cm) N0 medically operable NSCLC • SBRT (54 Gy in 3 fractions, 50 Gy in 4 fractions if central) vs lobectomy and mediastinal lymph node dissection. • 3-year OS improved for SBRT (95%) vs surgery (79%). Grade 3–4 toxicity 10% for SBRT vs 44% for surgery. SBRT VS SURGERY
  • 55. • JoLT-Ca STABLE-MATES trial (NCT02468024) • VALOR (Veterans Affairs Lung cancer surgery Or stereotactic Radiotherapy trial, NCT02984761) • SABRTOOTH (NCT02629458) Trials under going SBRT VS SURGERY
  • 56. Conclusion It is a form of high precision radiotherapy delivery technique • Needs to account for tumor motion • Needs to be accurate • Needs to have reproducible setup prior to treatment Indications • Stage I–II, inoperable, T1-3N0M0   Definitive SBRT not 3D • Medically inoperable • Operable disease who are high risk, elderly • Refuse surgery
  • 57. SABR for Node-Negative Early-Stage NSCLC • BED ≥100 Gy are associated with significantly better local control and survival • For central and ultra-central tumors 4 to 10 fraction regimens are effective and safe • SABR is most commonly used for tumors up to 5 cm in size SBRT has a Developing role • Boost following definitive chemoradiation in management of LA-NSCLC • Re-irradiation of locally recurrent disease • Intrathoracic oligometastases from various primary histologies

Editor's Notes

  1. Window width is range and window level is center point of width
  2. current physical and especially clinical data do not support the superiority of one particular strategy.
  3. Multiple co planar and non co planar beams are used
  4. Cancer specific survival